

VistaGen Therapeutics, Inc.  
 Form 4  
 December 24, 2013

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**Singh Shawn**

(Last) (First) (Middle)

C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO, CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

VistaGen Therapeutics, Inc. [VSTA]

3. Date of Earliest Transaction (Month/Day/Year)

12/20/2013

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 \_\_\_\_ Officer (give title below) \_\_\_\_\_ Other (specify below)

CHIEF EXECUTIVE OFFICER

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D) Price			
Common Stock	12/20/2013		A	100,000	A 100,000	I	By Trust
Common Stock					312,174	I	By Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

Edgar Filing: VistaGen Therapeutics, Inc. - Form 4

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Underlying (Instr. 3 and 4)
					V	(A)	(D)	Date Exercisable	Expiration Date	
Stock Option (Right to Buy)	\$ 1.13	12/20/2013		D		60,000		03/24/2013	03/24/2019	Common Stock
Stock Option (Right to Buy)	\$ 0.5	12/20/2013		A	60,000			03/24/2013	03/24/2019	Common Stock
Stock Option (Right to Buy)	\$ 1.13	12/20/2013		D		22,500		12/17/2009	06/17/2019	Common Stock
Stock Option (Right to Buy)	\$ 0.5	12/20/2013		A	22,500			12/17/2009	06/17/2019	Common Stock
Stock Option (Right to Buy)	\$ 1.5	12/20/2013		D		1,000,000		11/04/2011	11/04/2019	Common Stock
Stock Option (Right to Buy)	\$ 0.5	12/20/2013		A	1,000,000			11/04/2011	11/04/2019	Common Stock
Stock Option (Right to Buy)	\$ 1.5	12/20/2013		D		425,000		12/30/2011	12/30/2019	Common Stock
Stock Option (Right to Buy)	\$ 0.5	12/20/2013		A	425,000			12/30/2011	12/30/2019	Common Stock
Stock Option (Right to Buy)	\$ 1.75	12/20/2013		D		100,000		<u>(3)</u>	04/26/2021	Common Stock

Edgar Filing: VistaGen Therapeutics, Inc. - Form 4

Stock Option (Right to Buy)	\$ 0.5	12/20/2013	A	100,000	(3)	04/26/2021	Common Stock
Stock Option (Right to Buy)	\$ 2.1	12/20/2013	D	40,000 (4)	01/17/2012	01/17/2018	Common Stock
Stock Option (Right to Buy)	\$ 0.5	12/20/2013	A	40,000 (4)	01/17/2012	01/17/2018	Common Stock
Warrant	\$ 1.75	12/20/2013	D	35,714	08/25/2008	12/31/2013	Common Stock
Warrant	\$ 0.5	12/20/2013	A	35,714	08/25/2008	12/31/2016	Common Stock
Warrant	\$ 1.5	12/20/2013	D	50,000	12/06/2012	12/06/2017	Common Stock
Warrant	\$ 0.5	12/20/2013	A	50,000	12/06/2012	12/06/2017	Common Stock
Warrant	\$ 1.75	12/20/2013	D	80,338	08/25/2008	12/31/2013	Common Stock
Warrant	\$ 0.5	12/20/2013	A	80,338	08/25/2008	12/31/2016	Common Stock
Warrant	\$ 1	12/20/2013	A	100,000	12/20/2013	07/30/2016	Common Stock

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Singh Shawn C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO, CA 94080			CHIEF EXECUTIVE OFFICER	

## Signatures

/s/ Jerrold D. Dotson,  
Attorney-in-Fact

12/24/2013

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Securities were issued to Reporting Person as additional consideration for the purchase of a promissory note in the principal amount of \$50,000.
- (2) The Reporting Person agreed to cancellation of an option granted to him on May 11, 2011 in exchange for a new option having a lower exercise price.
- (3) Options vest monthly over a period of four years commencing April 25, 2011, with a twelve-month cliff of 25% of the shares.
- (4) Two identical grants for 20,000 shares each have been combined into one line item.
- (5) The Reporting Person agreed to cancellation of a warrant issued 8/25/2008 in exchange for a new warrant having a lower exercise price and extension of the term.
- (6) Held by The 1997 Singh Family Trust U/R/D 5/29/97.
- (7) The Reporting Person agreed to cancellation of a warrant issued 12/06/2012 in exchange for a new warrant having a lower exercise price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.